Endoscopic management offers acceptable oncologic control in select patients with upper tract urothelial carcinoma (UTUC) while preserving renal function. Adjuvant intracavitary treatment with chemotherapy or Bacillus Calmette-Guérin (BCG) has been proposed to reduce recurrence risk. We aimed to evaluate the impact of adjuvant intracavitary treatment on ipsilateral UTUC recurrence following endoscopic management. We queried a multi-institutional cohort of patients who underwent endoscopic management for UTUC. Treatment groups were defined as no instillation, single post-operative instillation, or multiple instillations. Ipsilateral UTUC recurrence-free survival (RFS) was estimated using Kaplan-Meier curves and Cox proportional hazards models evaluated factors associated with recurrence. A total of 599 renal units, of which 43 received single instillation and 86 multiple instillations, in 334 patients treated endoscopically for UTUC were analyzed. The median follow-up time for patients without recurrence was 12 months (IQR 4–33). Multiple adjuvant instillations of any intracavitary treatment were associated with a significantly improved RFS (HR 0.52, 95
Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy over 48 weeks in patients aged ≥ 12 years with alopecia areata (AA) in the ALLEGRO phase 2b/3 study and initial extension up to month 24 in the ALLEGRO-LT study. We aimed to evaluate the efficacy of ritlecitinib up to 3 years in patients with AA from the ALLEGRO phase 2b/3 and ongoing phase 3, open-label ALLEGRO-LT studies. Patients aged ≥ 12 years with AA and ≥ 50
Optimal management of symptomatic walled-off pancreatic necrosis (WOPN) continues to evolve, yet current guidelines provide limited direction across treatment options. This systematic review and meta-analysis compared WOPN interventions to inform forthcoming clinical guidelines by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). A systematic review through January 24, 2025, addressed four key questions (KQs): (1) image-guided versus endoscopic, (2) image-guided versus surgical, (3) endoscopic versus surgical, and (4) pure endoscopic versus the step-up approaches. Randomized controlled trials (RCTs) and comparative observational studies were included. Meta-analyses used random-effects models. Certainty of evidence (CoE) was assessed using GRADE. Reporting followed PRISMA 2020. Compared to endoscopic (KQ1), image-guided intervention may be associated with higher mortality (OR: 4.80), increased combined and surgical reintervention (OR: 3.94), more severe complications (OR: 5.42), and longer hospital stay (OR: 15.75). Compared to open surgery (KQ2), image-guided intervention may be associated with lower mortality (OR: 0.40) and fewer radiologic reinterventions (OR: 0.14), but higher surgical reintervention (OR: 4.28). No significant differences were observed compared with minimally invasive surgery (MIS). In RCT data, endoscopic and MIS approaches (KQ3) may have similar outcomes, with no significant differences in mortality, complications, or reintervention. For pure endoscopic vs step-up approaches (KQ4), RCT data suggest that an endoscopic-only strategy may be associated with fewer severe complications (OR: 0.36) but higher rates of radiologic (OR: 4.48) and endoscopic reinterventions (OR: 2.96), with no clear difference in mortality. Endoscopic management may be associated with more favorable outcomes than image-guided interventions. Image-guided intervention may be associated with lower mortality than open surgery but increased surgical reintervention. Endoscopic and MIS approaches may be equally effective. Endoscopic-only approaches may reduce severe complications at the cost of more reinterventions than the step-up approach. Overall, CoE is very low, highlighting the need for high-quality, multicenter RCTs.
Antithrombotic-associated intracranial hemorrhage (ICH) is a life-threatening condition, and rapid treatment in the setting of antithrombotic agents may limit hematoma expansion and improve outcomes. This focused update evaluated the available evidence after publication of the 2016 guidelines. The Neurocritical Care Society, in conjunction with the Society of Critical Care Medicine, generated five questions to guide a systematic review and meta-analysis. Three of these questions update prior recommendations, while two are newly introduced. Each question followed a Population, Intervention, Comparator, Outcome (PICO) framework and focused on the management of acute ICH including spontaneous intraparenchymal hemorrhage (IPH) and traumatic ICH. The topics addressed were: (1) andexanet alfa versus 4-factor prothrombin complex concentrate (4F-PCC) for treatment of oral factor Xa inhibitor effects; (2) platelet transfusion versus no transfusion for treatment in the setting of antiplatelet agent use; (3) desmopressin versus no desmopressin for treatment in the setting of antiplatelet agent use; (4) treatment of anticoagulant effects versus no treatment in the setting of small IPH; and (5) use of viscoelastic hemostatic assays (VHAs) to treat coagulopathy in traumatic ICH. Recommendations were developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. The panel generated eight recommendations. For patients with acute ICH, the panel issued the following conditional recommendations: use 4F-PCC rather than andexanet alfa for the treatment of the anticoagulant effects of factor Xa inhibitors, avoid platelet transfusion in non-neurosurgical patients with spontaneous IPH on antiplatelet agents, administer platelet transfusion in patients with spontaneous IPH on aspirin who are undergoing surgery, and use VHAs to guide treatment of coagulopathy in traumatic ICH. The panel was unable to issue recommendations regarding platelet transfusion for treatment of antiplatelet effects in traumatic ICH, use of desmopressin for treatment of antiplatelet effects, or treatment of anticoagulant effects in small IPH. The guideline writing panel provided new conditional recommendations for the treatment of antithrombotic-associated acute ICH. These recommendations are intended for consideration along with the patient’s clinical status and patient-specific factors.
Observational data can provide evidence of treatment effects in a low-burden, cost-effective manner. Using a causal inference framework to address selection bias, we illustrate the approach in ALS by examining previously researched associations, baseline function and sex, and evaluating metformin's survival benefits. Data are from the ALS Natural History Study collected in the United States, Israel, and Italy from 2015 to 2025. We employ propensity score matching, two approaches to address loss to follow-up (i.e. a naive exclusion and principal stratification), and randomization-based inference to evaluate difference in 18-month restricted mean survival time. For the function investigation, estimated survival is 16.39, 16.14, 16.09, and 16.24 months for the high ALSFRS-R group and 14.04, 14.42, 14.72, and 14.60 months for the low ALSFRS-R group using the non imputed and imputed datasets 1-3, respectively (p<0.0001, N=450; p<0.00001, N=1,485; p<0.00001, N=1,492; p<0.00001, N=1,600). Using principal stratification, estimated survival is 16.38, 16.14, 16.09, and 16.23 months for the high ALSFRS-R group and 14.04, 14.42, 14.72, and 14.59 months for the low ALSFRS-R group with the non imputed and imputed datasets 1-3, respectively (p<0.0001, N=449; p<0.00001, N=1,483; p<0.00001, N=1,491; p<0.00001, N=1,596). For the sex investigation, estimated survival is 15.20, 15.16, 15.20, and 15.17 months for females and 15.41, 14.84, 14.91, and 14.97 months for males using the non imputed and imputed datasets 1-3, respectively (p≈0.594, N=612; p≈0.155, N=2,081; p≈0.200, N=2,104; p≈0.359, N=2,111). Using principal stratification, estimated survival is 15.20, 15.16, 15.20, and 15.17 months for females and 15.41, 14.83, 14.91, and 14.97 months for males with the non imputed and imputed datasets 1-3, respectively (p≈0.598, N=612; p≈0.146, N=2,079; p≈0.195, N=2,102; p≈0.364, N=2,110). For the metformin investigation, estimated survival is 14.77, 14.87, and 14.57 months for metformin users and 14.59, 14.43, and 13.97 months for non metformin users using imputed datasets 1-3, respectively (p≈0.391, N=289; p≈0.257, N=279; p≈0.191, N=301). Using principal stratification, estimated survival is 14.75, 14.85, and 14.55 months for metformin users and 14.68, 14.58, and 13.97 months for non metformin users with imputed datasets 1-3, respectively (p≈0.458, N=286; p≈0.351, N=275; p≈0.201, N=300). We reject the sharp null hypothesis for the function investigation and fail to reject it for the sex and metformin investigations. ### Competing Interest Statement S. Ajroud-Driss has received research funding from Biogen, Edgewise Therapeutic, Woolsey pharmaceuticals, Uniqure biopharma, Coya therapeutics, Alnylam pharmaceuticals, MGH-Healey center, Hopewell, MT pharma, Loma Linda, Les Turner's ALS foundation, NIH, university of Minesota and FDA and received consulting fees from AstraZeneca and Biogen. F. Cerri has received funding from Fondazione Italiana di Ricerca per la SLA; she has served on medical advisory boards for Biogen, Italfarmaco, Zambon. M. Ghasemi receives clinical trials funding from Biogen, Prilenia, NIH/NINDS/Mass General Hospital, and Sean M. Healey and AMG Center for ALS. K. Gwathmey has received grants from the ALS Association and CDC, and has clinical trial funding from Sean Healey and AMG Center for ALS and Zydus, and clinical research projects sponsored by the FDA, NIH/NINDS. T. Heiman-Patterson has received grants from the ALS Association, Tanabe Pharma America, Amylyx and has clinical trials funding from Novartis, Amylyx, Sean Healey and AMG Center for ALS,Arcellx, and Coya. She has served on medical advisory boards for Corcept, Amylyx, Tanabe Pharma America and AB Sciences. C. Lunetta has received funding from the Italian Ministry of Health; he has served as an occasional scientific consultant for Biogen, Tanabe, Cytokinetics, Neuraltus, Italfarmaco, and Zambon. D. Walk has received funding from the FDA; he reports no other funding relevant to the manuscript. J. Wymer receives funding from MT Pharma and is a principal investigator for a clinical trial investigating metformin in people living with C9orf72-ALS ([NCT04220021][1]). A. V. Sherman has received grants and contracts for clinical research projects sponsored by the FDA, NIH/NIA, NIH/NINDS, The ALS Association, Sean M. Healey and AMG Center for ALS, and ALS Finding a Cure Foundation, as well as study support from Tanabe Pharma America, Inc., Biogen, and Amylyx. The remaining authors report no disclosures relevant to the manuscript. ### Funding Statement The project described was supported by funding from the ALS Association, ALS Finding A Cure Foundation, the ALS and O'Hagen ALS-PLS funds of the University of Minnesota Foundation, the ALS Hope Foundation, Biogen, Harper's Hope Fund, the Harry J Hoenselaar Endowment, the Les Turner ALS Foundation, Mitsubishi Tanabe Pharma America and by Grant Number RO1-FD007630 from FDA's Office of Orphan Products Development. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the FDA nor FDA's Office of Orphan Products Development. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The written informed consent was obtained from all participants in the study. The data we use in the publication is de-identified. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The study protocol and the dataset used in the paper will be made available upon request to the corresponding author. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT04220021&atom=%2Fmedrxiv%2Fearly%2F2026%2F03%2F13%2F2026.03.11.26347714.atom